Technivie Lawsuit
The Hepatitis C medication, Technivie, has ben associated with liver injury, liver failure and reactivation of the Hepatitis B virus in co-infected patients. Filing a Technivie lawsuit may be an option for individuals who suffered serious side effects while using this medication.
Contact a Technivie Lawyer
The nationwide law firm of Bernstein Liebhard LLP is evaluating potential Technivie lawsuits involving:
- Serious liver injuries
- Liver failure
- Reactivation of hepatitis B virus
If you or a loved one experienced any of these issues while undergoing treatment with Technivie, please call (888) 994-5118 to contact our attorneys today.
FDA Technivie Warnings
Technivie is an oral, direct-acting antiviral approved to treat patients with genotype 4 chronic Hepatitis C. Technivie’s active ingredients include ombitasvir, paritaprevir and ritonavir. It is indicated to be used in conjunction with ribavirin. Since granting Technivie approval in July 2015, the U.S. Food & Drug Administration (FDA) has issued a number of safety alerts for it and other direct-acting antivirals:
- October 2015: The FDA warned that Technivie and Viekira Pak could cause serious liver injury including liver failure. The warning came after the agency’s review identified 26 cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines. In most cases, the liver injury occurred within 1 to 4 weeks of starting treatment. Patients taking these medicines should contact their health care professional immediately if they develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be signs of liver injury.
- October 2017: The FDA ordered the manufacturers of Technivie and other direct-acting antivirals to add a Black Box Warning regarding a potential for reactivation of the Hepatitis B virus in co-infected patients. According to the agency, 24 cases of Hepatitis B reactivation had been reported in relation to direct-acting antivirals from November 22, 2013 to July 18, 2016. Two patients died and one required a liver transplant. Technivie patients co-infected with Hepatitis C and B should contact their doctor if they experience any signs or symptoms of Hepatitis B reactivation, including fatigue; weakness; loss of appetite; nausea and vomiting; or yellowing of the eyes or skin.
Filing a Technivie Lawsuit Can Help
Technivie patients who suffered serious liver injuries, liver failure or Hepatitis B virus reactivation may be entitled to compensation for injury-related damages, including:
- Medical bills
- Lost wages
- Disability
- Emotional distress
- Wrongful death
Patients and their families interested in filing a Technivie lawsuit can obtain a free, no-obligation case review by calling (888) 994-5118.
- FDA (2015) “FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie” http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm
- FDA (2016) “FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C: http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.
Follow Us
